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reductase causes autosomal dominant
dopa-responsive dystonia
ABSTRACT
Objective: To elucidate the genetic cause of an Egyptian family with dopa-responsive dystonia
(DRD), a childhood-onset dystonia, responding therapeutically to levodopa, which is caused by
mutations in various genes.
Methods: Rare variants in all coding exons of GCH1were excluded by Sanger sequencing. Exome
sequencing was applied for 1 unaffected and 2 affected family members. To investigate the
functional consequences of detected genetic variants, urinary sepiapterin concentrations were
determined by high-performance liquid chromatography.
Results: A heterozygous rare nonsynonymous variant in exon 1 of sepiapterin reductase (SPR,
c.207C.G, p.Asp69Glu) was found in all affected family members. Urinary concentrations of
sepiapterin were above the standard of normal controls in most SPR mutation carriers, suggest-
ing functional biochemical consequences of the mutation. Variant filtering of all genes involved in
the tetrahydrobiopterin pathway, required for levodopa synthesis, revealed an additional common
variant in dihydrofolate reductase (DHFR, rs70991108). The presence of both variants was
significantly stronger associated with the biochemical abnormality and the clinical disease state
as opposed to 1 variant only.
Conclusions: The rare SPR mutation can cause autosomal dominant DRD with incomplete pene-
trance. The common DHFR variant might have synergistic effects on production of tetrahydro-
biopterin and levodopa, thereby increasing penetrance. Neurol Genet 2017;3:e197; doi: 10.1212/
NXG.0000000000000197
GLOSSARY
DHFR 5 dihydrofolate reductase; DRD 5 dopa-responsive dystonia; MAF 5 minor allele frequency; NADPH 5 nicotinamide
adenine dinucleotide phosphate; SPR 5 sepiapterin reductase.
Dopa-responsive dystonia (DRD) encompasses a group of movement disorders with heteroge-
neous clinical and genetic manifestations, presenting with childhood-onset limb dystonia and
response to levodopa therapy.1 Additional neurologic presentations may include parkinsonian
and pyramidal features.2,3 Variants in the gene of GTP cyclohydrolase I (GCH1), a key protein
of the tetrahydrobiopterin (BH4) pathway, required for the biosynthesis of levodopa (figure, A),
are the most frequent cause of autosomal dominant DRD, also known as DYT5a.1,4 Variants of
sepiapterin reductase (SPR), encoding another key protein of the BH4 pathway (figure, A), have
been identified in autosomal recessive DRD.5 At present, only 1 patient with DRD without
family history has been identified with a heterozygous SPR variant.6 Here, we describe the first
DRD family carrying a rare SPR variant (c.207C.G, p.Asp69Glu, chr2:73114768_C.G,
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undetected in 8,599 alleles annotated in the
Exome Variant Server) with autosomal domi-
nant inheritance and incomplete penetrance.
METHODS Standard protocol approvals, registrations,
and patient consents. Affected and nonaffected individuals of
a family of Egyptian origin were examined by neurologists special-
ized in movement disorders (A.S.S. and G.U.H.) at the
Department of Neurology, Ain Shams University, Cairo, Egypt.
Ethical approval was obtained at Ain Shams University (RP/42)
and Technical University of Munich (203/15s). All participants
provided written informed consent. Consanguinity was excluded
by interview and genetic analyses.
Sanger and next-generation sequencing. After excluding
known rare variants in all 6 coding exons of GCH1 by Sanger
sequencing, exome sequencing was applied to 1 unaffected and 2
affected family members. Genomic DNA libraries were captured
using the Nextera Rapid Capture Expanded Exome Kit (Illumina,
San Diego, CA), and DNA fragments were sequenced on an Illu-
mina HiSeq2000 system. Variants were identified by a standard
analysis pipeline.
Variant filtering and validation. Variants with a minor allele
frequency (MAF) .0.1%, based on .6,500 (The National
Heart, Lung, and Blood Institute Exome Sequencing Project,
version ESP6500siv2), were discarded. Assuming a dominant dis-
order, only nonsynonymous variants were retained as candidate
alleles, including missense, nonsense, stop-loss, and splice-site
mutations, as well as small insertions and deletions present in
the heterozygous state and present in both affected sisters (figure
B, II.2 and II.4). Hypothesis-based variant filtering was applied to
all genes in the SPR pathway, also considering variants with an
MAF .1.0%. Candidate variants were validated by Sanger
sequencing and cosegregation with disease in the family (table 1).
In silico analyses. The effects of amino acid substitutions on pro-
tein function were predicted using MutationTaster (mutationtaster.
org), PolyPhen-2 (genetics.bwh.harvard.edu/pph2), and CADD
(cadd.gs.washington.edu). Mutagenesis analysis was performed with
PyMOL (pymol.org) based on the SPR protein structure 4XWY
(PDB file). Functional protein domains were analyzed using Hap-
loReg v4.1 (broadinstitute.org/mammals/haploreg/haploreg.php).
Urinary sepiapterin. First-void urine was collected, protected
from light, immediately placed on dry ice, and stored at 280°C.
For sepiapterin quantification, samples were prepared as
described7 and subjected to high-performance liquid chromatogra-
phy analysis on a C18 reversed-phase column (Spherisorb ODS1,
5 mm, ID 4.6 mm, L250 mm; Waters, Milford, MA) and
isocratic elution with 24 mM KH2PO4 (pH 5.0)/CH3OH
Figure Sepiapterin reductase and dihydrofolate reductase in the context of dopa-responsive dystonia
(A) Synthesis and regeneration of 5,6,7,8-tetrahydrobiopterin (BH4), an essential cofactor of L-DOPA synthesis (scheme adapted from references 3, 11).
Proteins of relevance are highlighted in red and blue. AR 5 aldose reductase; CR 5 carbonyl reductase; DHPR 5 dihydropteridine reductase; PCD 5 pterin-
4a-carbinolamine reductase; TH 5 tyrosine hydroxylase; 29-Oxo-TP 5 19-hydroxy-29-oxopropyltetrahydrobiopterin; 19Oxo-TP 5 29-hydroxy-19-oxopropyl-
tetrahydrobiopterin. (B) Pedigree of the investigated dopa-responsive dystonia family. Sepiapterin reductase (SPR) C/G5 chr2:73,114,768 C/G in exon 1 of
SPR; dihydrofolate reductase (DHFR)-/Ins 5 chr5:79,950,163-/TGGCGCGTCCCGCCCAGGT (19 base-pair insert) intronic, located upstream of exon 5 of
DHFR. Green asterisks indicate family members with urine sepiapterin values slightly above the concentration range measured in normal controls.
(C) Structure of the NADP-binding site in chain A of SPR obtained from the Research Collaboratory for Structural Bioinformatics protein data bank (identifier
5 4XWY) in wild-type (left) and mutant states (right). Aspartate on position 69 forms hydrogen bonds (green dashed lines) with cofactor nicotinamide
adenine dinucleotide phosphate (NADPH) (colored in black). In the case of a substitution of aspartate with glutamate, a loss of hydrogen bonds is predicted
(dashed red line).
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(85:15, vol/vol) (flow rate 1.1 mL/min over 15 minutes). A fluo-
rescence detector (RF 20A XS; Shimadzu, Kyoto, Japan; excitation
l 5 425 nm; emission l 5 530 nm) was used. Sepiapterin eluted
with a retention time of 9.9 minutes. Urine samples were masked
before analysis. Mean values of 4 technical measurements are
presented.
Statistical analyses. Descriptive analyses and x2 statistics were
calculated using Statistica 8.0 (StatSoft Inc., Tulsa, OK). Data are
presented as mean 6 SEM. p , 0.05 was considered statistically
significant.
RESULTS Clinical description. We examined 5
affected and 4 nonaffected family members
(figure, B). Symptom onset was between childhood
and puberty (table 2). Patient II.4 presented with
lower limb dystonia (tiptoe walking) and rigidity
since childhood, with progressive course and diurnal
variation. He improved markedly with L-DOPA,
however with low-threshold drug-induced dyskine-
sia. His current medication comprises fractionated
L-DOPA doses (750 mg/d), anticholinergics, and
amantadine (400 mg/d). The other affected in-
dividuals showed diurnal lower limb dystonia, rigid-
ity, and mild pyramidal signs. Patients (II.2 and II.5)
experienced symptomatic benefit with L-DOPA and
continued on pramipexole. Patients III.2 and III.3
were not treated with L-DOPA because of their young
age, mild symptoms, and fear of their parents of
L-DOPA–induced dyskinesia.
Genetic analysis. We found a nonsynonymous hetero-
zygous variant in exon 1 of SPR (NM_003124.4
c.207C.G, p.Asp69Glu, genomic [GRCh37]:
chr2:73114768_C.G) in all affected family mem-
bers. In SPR, aspartate 69 is involved in binding
the cofactor nicotinamide adenine dinucleotide phos-
phate (NADPH). In silico mutagenesis analysis pre-
dicted that the longer and more flexible side chain of
glutamate 69 in mutation carriers leads to an
increased distance and loss of hydrogen bonds to
NADPH (figure, C).
Structural gene/exon variations of SPRwere checked
in the 3 samples in which whole-exome sequencing was
performed using the BreakDancer tool (github.com/
genome/breakdancer).8 We did not detect such an
event near SPR or elsewhere on chromosome 2.
In addition, we found an intronic 19 base-pair
insertion (rs70991108) in an active transcription start
site of the dihydrofolate reductase (DHFR) gene in all
affected family members (table 2). This variant alters
8 regulatory motifs (HaploReg).
Urinary sepiapterin. SPR deficiency increases urinary
sepiapterin levels.7 To investigate the consequences
of the variants observed in this study, we measured
urinary sepiapterin concentrations in all members
(table 2). All clinically affected family members
had sepiapterin concentrations slightly above the
range measured in normal controls (mean 6 SD:
4.2 6 3.12 mmol/mol creatinine), but below the
values in proven SPR-deficiency patients (727 6
230 mmol/mol creatinine).7
Genotype-phenotype relationship. The family member
without the SPR variant (II.1) had normal sepiapterin
concentrations and was healthy. From the 8 SPR var-
iant carriers (table 2), 7 had elevated sepiapterin con-
centrations; 5 of those were clinically affected.
From 2 members without the DHFR variant
(I.2 and III.1), 1 had elevated sepiapterin values,
but both were healthy. From 7 DHFR variant carriers
(table 2), 6 had elevated sepiapterin concentrations;
5 of those were clinically affected.
Six family members carried both SPR and DHFR
variants (table 2); all of them had elevated sepiapterin
concentrations; 5 of them were clinically affected.
There was a significantly stronger association of
both variants simultaneously with the biochemical
abnormality (x2 5.1429, p , 0.05) and the clinical
disease state (x2 5.625, p , 0.05) as opposed to only
1 variant.
Table 1 Primer sequences for the SPR gene encoding sepiapterin reductase (SPR) and for rs70991108 located in the DHFR gene encoding
dihydrofolate reductase (DHFR)
Oligo name Sequence Orientation
Primer
length Tm
GC content,
%
Length
product Gene
Annealing
temperature, °C
SPR_Ex1_F CCCGCCGACACCCGTA Forward 16 61.19 75 466 SPR 59.9
SPR_Ex1_R CCCTTAAATTCCCCAGCGGT Reverse 20 60.03 55
SPR_Ex2_F GCATGGGAAGAGGATATCTGG Forward 21 57.65 52.38 462 SPR 59.9
SPR_Ex2_R GGACTAGGCCGCTTGC Reverse 16 57.21 68.75
SPR_Ex3_F ACCCCCGACATAAAACAGGG Forward 20 59.67 55 473 SPR 55.3
SPR_Ex3_R CACAGCACAGACTCCTGACA Reverse 20 59.61 55
DHFR_rs70991108_F AGAAAAGGGGAATCCAGTCG Forward 20 57.21 50.00 473 DHFR 60.4
DHFR_rs70991108_R GAGACATGGCAGGGCAAG Reverse 18 58.08 61.11
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DISCUSSION We identified a rare heterozygous var-
iant of SPR in a family with DRD segregating as
autosomal dominant trait (figure, B and table 2).
SPR is essential for levodopa synthesis. In silico anal-
ysis suggested pathogenicity of this variant. Consis-
tently, we found slightly elevated urine sepiapterin
concentrations in 7 variant carriers, 5 of these pre-
senting clinical symptoms. Since also 3 nonaffected
siblings carried this variant, incomplete penetrance
was assumed. Other SPR variants are known to cause
autosomal recessive DRD. A heterozygous SPR vari-
ant in a single patient with DRD without family
history had already indicated the possibility of auto-
somal dominant causality of SPR variants.6 These
observations suggest that this SPR variant has autoso-
mal dominant pathogenicity with incomplete
penetrance.
In the same family, we also identified a DHFR
variant (rs70991108). In silico analysis suggested
a potential effect of this variant on protein expression.
Consistently, we found elevated urine sepiapterin
concentrations in 6 and clinical symptoms in 5 of
the 7 variant carriers. Two nonaffected siblings car-
ried the variant as well. Because of its relatively high
allele frequency in the general population,9 we do not
assume this variant to be pathogenic per se.
Of interest, the presence of the common DHFR
variant in addition to the SPR variant significantly
increased the risk of the presence of the biochemical
abnormality (elevated sepiapterin urine concentra-
tions) and of clinical symptoms. The 1 sibling carry-
ing both variants (SPR and DHFR) without clinical
DRD symptoms might be either in a preclinical dis-
ease stage or might be protected by unknown resil-
ience factors.
While high DHFR expression in the liver may
account for a modest biochemical phenotype in the
periphery, the very low cerebral DHFR expression
might be further reduced by the variant, leading to
a clinically significant disturbance of L-DOPA synthe-
sis.10 This suggests that the presence or absence of
the common DHFR variant affects the penetrance of
the autosomal dominant SPR variant. With regard to
the sequential metabolic function of the SPR and
DHFR gene products in the L-DOPA synthesis path-
way (figure, A), this interpretation appears plausible.
The SPR-DHFR pathway metabolizes sepiapterin
to generate tetrahydrobiopterin, essential for the
Table 2 Clinical, genetic, and biochemical data of the investigated DRD family
Family
member Sex
Age at
examination, y Dystonia
Disease
onset
Phenomenology
(in chronological order)
Response to
L-DOPA
Variant
Sepiapterin
(mmol/mol Cr) 6 SEMSPR DHFR
I.1 M ND NA NA NA NA NA NA NA
I.2 F 56 2 2 2 ND 1 2 3.75 6 0.63
II.1 M 35 2 2 2 ND 2 1 2.99 6 0.53
II.2 F 32 1 Childhood Dystonic posturing of
both feet; with diurnal fluctuation,
mild lower limb bradykinesia and
rigidity, and extensor
planter responses
1 1 1 15.44 6 2.07a
II.3 M 29 2 2 2 ND 1 1 8.47 6 0.72a
II.4 F 27 1 Childhood Initially; lower limb dystonia,
bradykinesia, and rigidity with
diurnal variation progressed to
generalized parkinsonism;
L-DOPA–induced
dyskinesia and pyramidal signs
1 1 1 28.43 6 4.02a
II.5 M 21 1 Puberty Lower limb dystonia (tiptoe walking)
after prolonged walking;
bilateral lower
limb rigidity, postural tremor,
and equivocal Babinski sign
1 1 1 7.39 6 0.88a
III.1 M 14 2 2 2 ND 1 2 17.74 6 3.92a
III.2 F 10 1 Childhood Tiptoe walking with activity;
fast fatigability with dystonic
posturing on the left foot
ND 1 1 22.67 6 4.75a
III.3 M 5 1 Infancy Tiptoe walking; equinovarus
deformity
ND 1 1 19.95 6 2.40a
Abbreviations: Cr 5 creatinine; DHFR 5 dihydrofolate reductase; DRD 5 dopa-responsive dystonia; NA 5 not available; ND 5 not determined; SPR 5
sepiapterin reductase;25 not present; 15 present; variant DHFR 5 chr5:79,950,163-/TGGCGCGTCCCGCCCAGGT (19 base-pair insert); variant SPR 5
chr2:73,114,768 C/G in exon 1.
Normal range of urine sepiapterin: 4.2 6 3.12 mmol/mol Cr (mean of 10 controls without mutations in genes involved in the synthesis of L-DOPA).
a Elevated values.
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formation of L-DOPA. The enzymes SPR and DHFR
are serially catalyzing this reaction. Homozygous muta-
tions affecting SPR on both homologous chromosomes
impose a massive bottleneck within this pathway and
are known to cause DRD. A heterozygous mutation
affecting SPR on only 1 chromosome imposes a minor
bottleneck for this pathway. The clinical penetrance of
this condition may thus depend on additional cofactors
affecting this pathway, such as epigenetic silencing of
the healthy SPR allele. In our family, this cofactor seems
to be the co-occurrence of an additional variant in the
downstream enzyme DHFR, causing a “tandem steno-
sis” within this pathway.
Taken together, the present study proposes the
rare SPR c.207C.G variant as a cause of autosomal
dominant DRD with incomplete penetrance and the
common DHFR rs70991108 variant as a potential
modifier, significantly affecting the penetrance of
the SPR variant.
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